Pharmacological induction of fetal hemoglobin synthesis using histone deacetylase inhibitors.
A number of pharmacological agents are currently available for the induction of the fetal hemoglobin (Hb F) to treat the patients with sickle cell disease and beta-thalassemia. In the present review, we summarized the investigation and development of these Hb F-inducing agents and introduced histone deacetylase inhibitors as the new strategy to induce Hb F to treat the hemoglobin disorders
Cao
Hua
H
Division of Medical Genetics, University of Washington, Seattle 98195, USA. huacao@u.washington.edu
D000755:Anemia, Sickle Cell / Q000188:drug therapy; D001374:Azacitidine / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000627:therapeutic use*; D005319:Fetal Hemoglobin / Q000096:biosynthesis*; D056572:Histone Deacetylase Inhibitors; D006801:Humans; D006918:Hydroxyurea / Q000627:therapeutic use; D017086:beta-Thalassemia / Q000188:drug therapy
D004791:Enzyme Inhibitors; D056572:Histone Deacetylase Inhibitors; D005319:Fetal Hemoglobin; D001374:Azacitidine; D006918:Hydroxyurea